FDA OKs Lumateperone for Schizophrenia Relapse Prevention

Published Date: 29 Apr 2026

Long-term data show the atypical antipsychotic reduced relapse risk by 63%, with 84% of patients with schizophrenia being relapse-free over 6 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

Is global cancer care losing its human touch?

3.

New study links air pollution with higher rates of head and neck cancer

4.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot